Navigation Links
KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
Date:8/7/2009

future events and trends.

All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, political and technological factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) the ability to continue as a going concern; (2) changes in the current and future business environment, including interest rates and capital and consumer spending; (3) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (4) the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals; (5) acceptance and demand for new pharmaceutical products; (6) the introduction and impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (7) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (8) reliance on key strategic alliances; (9) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (10) the regulatory environment, including regulatory agency an
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
2. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
3. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
4. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
5. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
8. ADVENTRX Pharmaceuticals Announces Financing
9. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 ... has announced the addition of the ... 2018" report to their offering. ... Lack of data protection and old security ... codes have driven the growth of biometric ...
(Date:6/19/2013)... June 19, 2013   NineSigma , Inc., of ... year following its launch, NineSights.com is now ... point for the worldwide community of innovators. ... environmental sustainability experts, NineSights stands out for its large ... scientific and technical disciplines, all vetted by NineSigma. The ...
(Date:6/19/2013)... June 19, 2013 BioConvergence team ... speaking faculty at 2013’s BioLogistics Summit in San ... coordinated by Cold Chain IQ and IQPC, addressed ... “complexity” is, in part, attributed to current trends ... “Implicit within these trends is an increase in ...
(Date:6/19/2013)... 2013 Adding to their already extensive ... with Simport’s Dropette® and Heathrow Scientific disposable plastic ... doing basic biology, chemistry and any type of liquid ... over 35 years, Simport has been supplying the science ... like the Simport Dropette®. Simport’s Dropette® is a one-piece ...
Breaking Biology Technology:Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... VANCOUVER, April 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... global specialty pharmaceutical and,medical device company, today ... the U.S. Food and Drug Administration (FDA) ... Catheter (CVC) in,the United States., "The ...
... with Increased Investment in ... Research & Development, DEERFIELD, Ill., April 17 ... for,the first quarter of 2008, and raised its financial outlook for the ... million, a 6,percent increase compared to $403 million in the first quarter ...
... and more transparency in federal risk research investment, the ... rather than a foregone conclusion, says Dr. Andrew Maynard, ... Nanotechnologies (PEN). This sentiment was voiced today by Dr. ... Committees hearing on the National Nanotechnology Initiative Amendments Act ...
Cached Biology Technology:Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 2Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 3Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 4Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance 5Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 2Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 3Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 4Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 5Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 6Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 7Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 8Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 9Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 10Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 11Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 12Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 13Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 14Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 15Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 16Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 17Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 18Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook 19Limited transparency in federal nanotech research may hamper development 2
(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...
(Date:6/18/2013)... University, sophisticated computational models and advances in graphical ... interplay between genomic data, virus structure and the ... for replication. , "We hope that ... researchers alter virus assembly, leaving viruses unable to ... of the scientific paper describing the technique, published ...
(Date:6/18/2013)... National Institutes of Health has awarded $12.7 million ... selection of pharmaceutical industry compounds to explore new ... Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. The ... for Existing Molecules, is led by the National ... by the NIH Common Fund. , The process ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... experimental drug prevented and treated both type 2 diabetes ... unhealthy diets and were genetically predisposed to these common ... on June 6, 2007. The team was led by ... Genetics and Complex Diseases at the Harvard School of ...
... very cold case: the disappearance of the last woolly mammoths, ... according to a June 7th report published online in Current ... the bones, teeth, and tusks of the extinct mammoths revealed ... interglacial period. After the mammoths’ migration, the population apparently leveled ...
... University of Minnesota researchers report that umbilical cord ... outcomes than bone marrow transplants, according to an ... for International Blood and Marrow Transplant Research (CIBMTR), ... the first study that directly compares matched bone ...
Cached Biology News:In mice, drug protects against diabetes and atherosclerosis 2In mice, drug protects against diabetes and atherosclerosis 3In mice, drug protects against diabetes and atherosclerosis 4Ancient DNA traces the woolly mammoth's disappearance 2Research shows cord blood comparable to matched bone marrow 2Research shows cord blood comparable to matched bone marrow 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... Plus Microsphere/Microarray Stabilizer is an aqueous solution ... other non-toxic chemicals in a PBS buffer ... This product contains a combination of ... preservative. StabilCoat Plus Stabilizer provides optimum ...
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
... data acquisition, analysis and experiment control ... data with on-line and off-line analysis. ... built-in script language allowing the user ... exact requirements. Applications range from basic ...
Biology Products: